JP2023518578A5 - - Google Patents
Info
- Publication number
- JP2023518578A5 JP2023518578A5 JP2022557922A JP2022557922A JP2023518578A5 JP 2023518578 A5 JP2023518578 A5 JP 2023518578A5 JP 2022557922 A JP2022557922 A JP 2022557922A JP 2022557922 A JP2022557922 A JP 2022557922A JP 2023518578 A5 JP2023518578 A5 JP 2023518578A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- cells
- virus
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993442P | 2020-03-23 | 2020-03-23 | |
| US62/993,442 | 2020-03-23 | ||
| PCT/IB2021/000158 WO2021191677A1 (en) | 2020-03-23 | 2021-03-22 | Compositions and methods for targeting hpv-infected cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518578A JP2023518578A (ja) | 2023-05-02 |
| JP2023518578A5 true JP2023518578A5 (https=) | 2024-04-03 |
Family
ID=77890979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557922A Pending JP2023518578A (ja) | 2020-03-23 | 2021-03-22 | Ｈｐｖ感染細胞を標的とするための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230348558A1 (https=) |
| EP (1) | EP4125949A4 (https=) |
| JP (1) | JP2023518578A (https=) |
| CN (1) | CN115867295A (https=) |
| AU (1) | AU2021243742A1 (https=) |
| WO (1) | WO2021191677A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024064716A2 (en) * | 2022-09-21 | 2024-03-28 | Providence Health & Services - Oregon | Human papillomavirus (hpv)-reactive t cell receptors and uses thereof |
| EP4716549A2 (en) * | 2023-05-22 | 2026-04-01 | Precigen, Inc. | T cell receptors generated as a result of hpv vaccine therapy and methods of treating patients with same |
| WO2025088530A1 (en) * | 2023-10-24 | 2025-05-01 | Treadwell Therapeutics | T cell receptors and methods of use thereof |
| TW202600816A (zh) * | 2024-02-20 | 2026-01-01 | 新加坡商新加坡星漢德生物醫藥有限公司 | 經修飾的靶向ｈｐｖ增強型免疫細胞及其醫藥用途 |
| WO2026047601A1 (en) * | 2024-08-28 | 2026-03-05 | BioNTech SE | T-cell receptors (tcrs) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| ES2745472T3 (es) * | 2013-07-15 | 2020-03-02 | The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra | Receptores de células T anti-virus del papiloma humano 16 E6 |
| DK3271382T3 (da) * | 2015-03-16 | 2020-05-04 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek |
| EP3156067A1 (en) * | 2015-10-16 | 2017-04-19 | Max-Delbrück-Centrum Für Molekulare Medizin | High avidity hpv t-cell receptors |
| WO2017079746A2 (en) * | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| JP2020537515A (ja) * | 2017-10-03 | 2020-12-24 | ジュノー セラピューティクス インコーポレイテッド | Ｈｐｖ特異的結合分子 |
| WO2019145792A1 (en) * | 2018-01-24 | 2019-08-01 | The Council Of The Queensland Institute Of Medical Research | Hpv immunotherapy |
| EP3773908A1 (en) * | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
-
2021
- 2021-03-22 CN CN202180036749.XA patent/CN115867295A/zh active Pending
- 2021-03-22 EP EP21774449.9A patent/EP4125949A4/en active Pending
- 2021-03-22 JP JP2022557922A patent/JP2023518578A/ja active Pending
- 2021-03-22 US US17/913,937 patent/US20230348558A1/en active Pending
- 2021-03-22 AU AU2021243742A patent/AU2021243742A1/en active Pending
- 2021-03-22 WO PCT/IB2021/000158 patent/WO2021191677A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518578A5 (https=) | ||
| JP7525558B2 (ja) | 二重特異性ｔ細胞アクチベーターで武装したアデノウイルス | |
| Saha et al. | Epstein-Barr virus–associated B-cell lymphomas: pathogenesis and clinical outcomes | |
| CN109485734B (zh) | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 | |
| US12054529B2 (en) | Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen | |
| JP7000315B2 (ja) | 高結合活性ｈｐｖ ｔ細胞受容体 | |
| JP6890831B2 (ja) | Ｈｉｖ予備免疫化および免疫療法 | |
| AU2018388079B2 (en) | Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, IL-7 and CCL19 | |
| ES3000183T3 (en) | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto | |
| JP2022512326A5 (https=) | ||
| CN110357952B (zh) | 识别人乳头瘤病毒hpv16-e7抗原的tcr | |
| CN114150018A (zh) | 治疗癌症的方法和组合物 | |
| WO2020156335A1 (zh) | 一种嵌合抗原受体及其应用 | |
| KR20210112310A (ko) | 종양 항원, tgf-베타 및 면역체크포인트를 표적으로 하는 tcr-t 세포 복합 치료법 | |
| CN105859890A (zh) | 嵌合抗原受体及其基因和重组表达载体、工程化cd30靶向性的nkt细胞及其应用 | |
| US20190192573A1 (en) | Anti-osteosarcoma car-t derived from the antibody oi-3 | |
| Perera Molligoda Arachchige | NK cell-based therapies for HIV infection: Investigating current advances and future possibilities | |
| WO2020025039A1 (zh) | 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用 | |
| KR20230035026A (ko) | 엡스타인-바 바이러스를 표적하는 tcr-t 세포 요법 | |
| Wlazlo et al. | DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins | |
| WO2020204086A1 (ja) | ２抗原を認識するｉＰＳ細胞由来キメラ抗原受容体発現Ｔ細胞療法 | |
| EP3833364A1 (en) | Dual function engineered t cells with hpv e6 specificity and pd-1 blockade | |
| CN117625545A (zh) | 经修饰的靶向hbv免疫细胞及其医药用途 | |
| US20230338422A1 (en) | Engineering gamma delta t cells with interleukin-36 for immunotherapy | |
| Wendtner et al. | High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus–free recombinant Epstein-Barr virus vectors |